Article
Axpaxli Superior to Aflibercept in Wet AMD Trial
Data from the phase 3 SOL-1 trial showed that Ocular Therapeutix’s intravitreal insert outperformed the standard of care, providing sustained visual maintenance and fluid control in treatment-naïve patients.







